International Symposium on Synthesis and Catalysis

	Full in person participation registration	On-line participation registration
Category	Price before July 26^th 2021 (€)	Price after July 26^th2021 (€)	Price before July 26^th 2021 (€)	Price after July 26^th2021 (€)
Portuguese Chemical Society membership? ^**	non-members	members	non-members	members	non-members	members	non-members	members
Academic	390	350	490	450	175	135	275	235
Industrial	580	540	680	640	220	180	320	280
Post-docs	310	270	410	370	120	80	220	180
Students ^*	210	170	310	270	80	40	180	140
Accompanying Person	150
Social Program	This will be indicated in due course

Plenary Speakers

Dr. Kevin Campos

Merck, USA

Prof. Armido Studer

University of Muenster, Germany

Prof. Phil Baran

Scripps (CA), USA

Dame Prof. Margaret Brimble

University of Auckland, New Zealand

Prof. Brian Stoltz

CALTEC, USA

Prof. Chaitan Khosla

Stanford University, USA

Prof. John Sutherland

Manchester University, UK

Prof. Klaus Mullen

Max Planck Institute for Polymer Research, Germany

Prof. Tim Noel

Eindhoven University of Technology, Holland

Dr. Oliver Thiel

Amgen, USA

Prof. Mariola Tortosa

Universidad Autónoma de Madrid, Spain

Dr. Alain de Mesmaeker

Syngenta, Switzerland

Prof. Gonçalo Bernardes

Cambridge University, UK

Dr. Rocco Paciello

BASF, Ludwigshafen, Germany

Plenary Talk Titles (under construction)

Phil Baran
Scripps (CA), USA
Translational Chemistry

Phil Baran

Scripps (CA), USA

Phil Baran was born in 1977 in Denville, New Jersey. He received his B.S. in chemistry from NYU in 1997, his Ph.D. at The Scripps Research Institute in 2001, and from 2001-2003 he was an NIH-postdoctoral fellow at Harvard. His independent career began at Scripps in the summer of 2003. He currently holds the Darlene Shiley Chair in Chemistry. Phil has published over 180 scientific articles and has been the recipient of several ACS awards such as the Corey (2015), Pure Chemistry (2010), Fresenius (2006), and Nobel Laureate Signature (2003), and several international distinctions such as the Hirata Gold Medal and Mukaiyama Prize (Japan), the RSC award in Synthesis (UK), and the Sackler Prize (Israel). In 2013 he was named a MacArthur Foundation Fellow, in 2015 he was elected to the American Academy of Arts and Sciences, in 2016 he was awarded the Blavatnik National Award, and most recently, in 2017, he was elected to the National Academy of Sciences, USA. He has delivered hundreds of lectures around the world and consults for numerous companies such as Bristol-Myers Squibb (since late 2005), Boehringer-Ingelheim, AstraZeneca, DuPont and TEVA, and is a scientific advisory board member for Eisai, Abide, and AsymChem. In 2016 he was appointed as an Associate Editor for the Journal of the American Chemical Society. He co-founded Sirenas Marine Discovery (2012) and Vividion Therapeutics (2016) and in 2013 he co-authored The Portable Chemist’s Consultant, an interactive book published on the iBooks store along with his graduate class in Heterocyclic Chemistry (viewable for free by anyone on iTunes University). Outside of the lab, Phil enjoys spending time with his wife Ana and three young children (Lucia, Leah, and Manuel).

Margaret Brimble
University of Auckland, New Zealand
Natural Products Synthesis: A Crucible for Mew Method Discovery

Margaret Brimble

University of Auckland, New Zealand

Dame Margaret Brimble FRS is the Director of Medicinal Chemistry and a Distinguished Professor at the University of Auckland where her research program focuses on the synthesis of bioactive natural products, antimicrobial peptides, cancer vaccines, glycopeptides, self-assembling peptides and peptidomimetics. She has published >500 papers, 78 reviews and is an inventor on >50 patents. In 2019 she was inducted into the American Chemical Society Medicinal Chemistry Division Hall of Fame and was awarded the BNZ Supreme Award and the Baldwins Researcher Entrepreneur Award in the Kiwinet Commercialization Awards. In 2018 she was elected a Fellow of the Royal Society London, awarded the Royal Society of Chemistry George and Christine Sosnovsky Award in Cancer Therapy and conferred the Queens Honour, Dame Companion of the New Zealand Order of Merit (DNZM). She won the 2016 Marsden Medal, the 2012 RSNZ Rutherford (NZ’s top science prize), MacDiarmid and Hector Medals, the 2011 Royal Australian Chemical Institute Adrien Albert Award, the 2010 RSC Natural Products Award, the 2007 L’Oreal-UNESCO Women in Science laureate in Materials Science for Asia-Pacific, a 2015 IUPAC Distinguished Women in Chemistry/Chemical Engineering Award. She is an Associate Editor for Organic Letters (American Chemical Society), Past-Associate Editor for Organic and Biomolecular Chemistry (Royal Society Chemistry), Past-President of IUPAC Organic and Biomolecular Division III, Past-President of the International Society of Heterocyclic Chemistry and Past-Chair of the Rutherford Foundation RSNZ. She discovered the first drug NNZ2566 named “trofinetide” to treat Rett Syndrome and Fragile X Syndrome that is in phase III clinical trials with Neuren Pharmaceuticals (http://www.neurenpharma.com) and Acadia Pharmaceuticals (USA). A second unique neurotrophic drug candidate NNZ-2591 also discovered by Professor Brimble’s lab has recently been demonstrated to give positive results in pre-clinical models of three additional neurodevelopmental disorders – Angelman syndrome, Pitt Hopkins syndrome and Phelan-McDermid syndrome. Neuren is filing an Investigational New Drug Application (IND) for NNZ2591 with the US Food and Drug Administration and commencing Phase 2 studies in the second half of 2020. Margaret also co-Founded the spin-out company SapVax (Cleveland, Ohio) with US$7 million funding from BioMotiv USA to take self-adjuvanting cancer vaccines based on a novel chemistry platform, to clinical trial (see: https://sapvaxllc.com). She has also entered a licensing and research and development agreement with the New Zealand company Living Cell Technologies (http://www.lctglobal.com) to progress two series of lipopeptide drug candidates to clinical trial for the treatment of obesity and migraine respectively.

Brian Stoltz
CALTEC, USA
Complex Natural Products as a Driving Force for Discovery in Organic Chemistry

Brian Stoltz

CALTEC, USA

Brian M. Stoltz was born in Philadelphia, PA in 1970. After spending a year abroad at the Ludwig Maximilians Universität in München, Germany, he obtained his B.S. degree in Chemistry and B.A. degree in German from the Indiana University of Pennsylvania in Indiana, PA. Following graduate work at Yale University in the lab of John L. Wood and an NIH postdoctoral fellowship at Harvard in the group of Professor E. J. Corey, he took a position at the California Institute of Technology. A member of the Caltech faculty since 2000, he is currently Professor of Chemistry. His research interests lie in the development of new methods for general applications in synthetic chemistry and biologically active small molecules. Among his many distinctions, Professor Stoltz has been the recipient of the Arthur C. Cope Scholar and the E. J. Corey Awards from the American Chemical Society, the Presidential Early Career Award in Science and Engineering (PECASE) from the White House, the 2009 Raymond and Beverly Sackler Prize in the Physical Sciences for Chemistry, and was the 2015 recipient of the Mukaiyama Award by the Society of Synthetic Organic Chemistry, Japan. He was named the recipient of the 2018 American Chemical Society Award for Creative Work in Synthetic Organic Chemistry and in 2019 became a Fellow of the American Chemical Society. Professor Stoltz has trained more than 200 students and postdocs, who have gone on to successful independent careers in industry and academia. In 2017, he was awarded the Richard P. Feynman Prize for Excellence in Teaching at Caltech, the highest honour for teaching at the institute and in 2020 became the editor-in-chief of Tetrahedron.

Armido Studer
University of Muenster, Germany
Boron an Emergent Element in Radical Chemistry

Armido Studer

University of Muenster, Germany

Armido Studer obtained a first degree from ETH Zürich (1987-1992), followed by a PhD at the same institution (1995, Supervisor: Prof. D. Seebach, asymmetric synthesis) this was followed by a Postdoctoral stint at Pittsburgh University (1995-1996, Supervisor: Prof. D. P. Curran, fluorous chemistry) and then habilitation studies at the ETH Zürich (1996-2000, radical chemistry). He was previously an associate professor at Marburg University (2000-2004, radical chemistry in synthesis and materials science) followed by promotion to full professor at the University of Münster (2004-present, radical chemistry, surface chemistry, catalysis). He has received numerous awards and distinctions, which include: Pedler Award RSC, 2019. Elected member of the North Rhine-Westphalian Academy of Sciences, Humanities and the Arts, 2018. Fujian “100 Talent Plan” Professor and Jiaxi Lu Guest Professorship, Chinese Academy of Sciences, Haixi Institutes, Fuzhou, 2018. Highly Cited Researcher 2017 and 2019. ERC Advanced Grant of the European Research Council, 2016. Research Award of the Westfälische Wilhelms University Münster, 2014. IOCF Yoshida Lectureship, Kyoto University, 2014. Spokesman of the German Research Council funded Collaborative Research Center SFB 858, since 2010. Guest Professorship: Université Bordeaux 1, Bordeaux, 2009. RSC / GE Healthcare Lecture, Cardiff, 2008. Guest Professorship: Pierre et Marie Curie, Paris, 2008. Solvias Ligand Contest Award, 2007. Novartis Young Investigator Award, 2006. Steinhofer Award at the University of Freiburg, 2005. He has also published numerous review articles on these themes.

Chaitan Khosla
Stanford University, USA
Mechanisms, Diversity, and Evolution of Assembly-Line Polyketide Synthases

Chaitan Khosla

Stanford University, USA

CHAITAN KHOSLA (Professor in the Departments of Chemistry and Chemical Engineering at Stanford University, and founding Director of Stanford ChEM-H) received his PhD in 1990 at Caltech. After completing postdoctoral studies at the John Innes Centre in the UK, he joined Stanford University in 1992. His work on antibiotic biosynthetic mechanisms led to new methods for engineering enzyme assembly lines to make novel anti-infective agents. He and his collaborators have also studied the molecular basis of celiac disease, a widespread but overlooked autoimmune disorder. He has co-authored over 350 peer-reviewed publications and 75 issued U.S. patents, and is the recipient of several awards and honors including the Eli Lilly Award in Biological Chemistry and the Pure Chemistry Award from the American Chemical Society, the Allan P. Colburn Award and the Professional Progress Award from the American Institute of Chemical Engineers, and the Alan T. Waterman Award from the National Science Foundation. He is an elected member of the American Academy for Arts and Science, the National Academy of Engineering, and the National Academy of Sciences. Over the past three decades, he has founded four biotechnology companies, and currently serves on the Board of Directors of Protagonist Therapeutics (PTGX).

Gonçalo Bernardes
Cambridge University, UK
Metal-mediated Bioorthogonal Bond-cleavage Reactions

Gonçalo Bernardes

Cambridge University, UK

Gonçalo Bernardes: After completing his D.Phil. in 2008 at the University of Oxford, U.K., he undertook postdoctoral work at the Max-Planck Institute of Colloids and Interfaces, Germany, and the ETH Zürich, Switzerland, and worked as a Group Leader at Alfama Lda in Portugal. He started his independent research career in 2013 at the University of Cambridge as a Royal Society University Research Fellow. In 2018 he was appointed University Lecturer (Tenured) and recently has been promoted to Reader (Associate Professor). Gonçalo is the recipient of two European Research Council grants, a starting grant and a proof-of-concept grant, and was awarded the Harrison–Meldola Memorial Prize in 2016 and the MedChemComm Emerging Investigator Lectureship in 2018, both from the Royal Society of Chemistry. His research group interests focus on the use of chemistry principles to tackle challenging biological problems for understanding and fight cancer.

John Sutherland
Manchester University, UK
Origins of Life Systems Chemistry

John Sutherland

Manchester University, UK

John Sutherland studied chemistry at the University of Oxford as an undergraduate, and then carried out his doctoral work there with the late Jack Baldwin. He stayed in Oxford first as a Junior Research Fellow and then as a University Lecturer in Organic Chemistry. In 1998 he took a chair in Biological Chemistry at Manchester, and in 2010 moved to the MRC Laboratory of Molecular Biology in Cambridge as a Programme Leader.
His research concerns the origin of life – how did chemistry initiate biology and to what extent did it shape its basic structure and function? His research to date has focused on establishing prebiotically plausible syntheses of the building blocks of the informational, catalytic and compartment–forming macromolecules crucial to life, and his group is now seeking to establish how these building blocks could have become linked together.
His group’s research has been recognised by his election as a Fellow of the Royal Society and the award of their Darwin Medal.

Prof. Klaus Mullen
Max Planck Institute for Polymer Research, Germany
Graphene nanoribbons as functional multitalents

Prof. Klaus Mullen

Max Planck Institute for Polymer Research, Germany

Klaus Müllen was director at the Max Planck Institute for Polymer Research and is continuing research at the universities of Heidelberg and Cologne. His broad research interests range from new polymer-forming reactions, to the chemistry and physics of single molecules as well as graphenes, dendrimers and biosynthetic hybrids. He published about 2000 papers. He received many awards, honorary doctorates and honorary professorships and he is member of national and international academies.
From 2008-2009 he served as president of the German Chemical Society (GDCh). In 2013-2014 he was president of the German Association for the Advancement of Science and Medicine. In 2010 he won an ERC Advanced Grant for his work on nanographenes. He is associate editor of the Journal of the American Chemical Society.

Dr. Oliver Thiel
Amgen, USA
Molecular Complexity as a Driver for Innovation in Pharmaceutical Process Development

Dr. Oliver Thiel

Amgen, USA

Oliver R. Thiel is currently the Executive Director for Drug Substance Technologies, Pivotal and Commercial Synthetics. His team supports the commercial process development and commercialization of the Amgen small molecule portfolio. Oliver has an undergraduate degree in Chemistry from the Technical University Munich, and he completed a Ph.D. from the Max-Planck-Institut für Kohlenforsching, Mülheim an der Ruhr under guidance of Prof. Alois Fürstner. After postdoctoral studies with Prof. Barry M. Trost at Stanford University he joined the Amgen Process Development organization in 2003. His teams supported multiple commercial products (Blincyto®, Carfilzomib®, Corlanor®, Imlygic®, Kanjinti®, Neulasta®, Parsabiv®, Sensipar®) and > 40 clinical development candidates. Oliver has over 50 peer-reviewed publications and has presented over 20 invited lectures.

Prof. Timothy Noël
Eindhoven University of Technology, Holland
Innovation in synthetic methodology through use of flow

Prof. Timothy Noël

Eindhoven University of Technology, Holland

Timothy Noël, born 1982 in Aalst (Belgium), received in 2004 his MSc degree (Industrial Chemical Engineering) from the KaHo Sint-Lieven in Ghent. He then moved to Ghent University to obtain a PhD at the Laboratory for Organic and Bioorganic Synthesis under the supervision of Professor Johan Van der Eycken (2005-2009). Next, he moved to Massachusetts Institute of Technology (MIT) as a Fulbright Postdoctoral Fellow with Professor Stephen L. Buchwald. At MIT, he worked on the development of new continuous-flow methods for cross-coupling chemistry at the MIT-Novartis Center for Continuous Manufacturing. After a stint as an associate professor and chair of the Micro Flow Chemistry & Synthetic Methodology group at Eindhoven University of Technology he moved in 2020 to the position of full professor and chair of flow chemistry at the Van´t Hoff Institute for Molecular Sciences at the University of Amsterdam. His research interests are flow chemistry, homogeneous catalysis and organic synthesis.
He received in 2011 the Incentive Award for Young Researchers from the Comité de Gestion du Bulletin des Sociétés Chimiques Belges, in 2012 a VENI award from NWO and he was also finalist of the European Young Chemist Award 2012. In 2013, he received a Marie Curie Career Integration Grant from the European Union. He coordinated the Marie Skłodowska-Curie ETN program “Photo4Future” on the development of photoredox catalysis in photomicroreactors (www.photo4future.com) (2015-2018). In 2015, he obtained a prestigious VIDI award from NWO. And in 2016, he received the Thieme Chemistry Journal Award. His research on photochemistry in microfluidic reactors was awarded the DECHEMA award 2017 and the Hoogewerff Jongerenprijs 2019. After 4 years as an associate editor of Journal of Flow Chemistry, he took over as editor in chief in 2019.
Website: www.NoelResearchGroup.com
Follow research in the Noël group via Twitter: @NoelGroupTUE

Dr. Kevin Campos
Merck, USA
Innovations in Synthetic Chemistry at MSD: Striving for the Ideal Commercial Manufacturing Process

Dr. Kevin Campos

Merck, USA

Kevin Campos received a B.S. degree in Chemistry from Virginia Tech in 1993. In 1999, he obtained his PhD in organic chemistry from Harvard University and joined the Department of Process Research at Merck as a Senior Research Chemist. Over the last 20 years, Kevin has established himself as a leader in both drug discovery and development. He is currently Associate Vice President and Head of Small Molecule Process Research and Development, where his team enables the small molecule pipeline, from discovery to commercial launch, through excellence in synthetic chemistry. Under his leadership, several commercial manufacturing routes for novel therapies have been launched for patients in need, including ZEPATIER™, PREVYMIS™, PIFELTRO™, ZERBAXA™ and RECARBRIO™, and his team has been recognized by the United States EPA and the American Chemical Society with the Green Chemistry Challenge award in 2017, 2018, and 2019.

Prof. Mariola Tortosa
Universidad Autónoma de Madrid, Spain
Stereoselective synthesis of sp3-rich building blocks

Prof. Mariola Tortosa

Universidad Autónoma de Madrid, Spain

Mariola Tortosa obtained her PhD at the Organic Chemistry Institute (CSIC, Madrid, Spain) under the supervision of Professor Fernández de la Pradilla (2005). In 2005, she moved to The Scripps Research Institute in Florida (USA) to work as a Postdoctoral Fellow with Prof. William R. Roush. In 2008 she returned to the Organic Chemistry Institute (Madrid, Spain) as a Research Assistant. In 2011 she started her independent career at the Universidad Autónoma de Madrid (UAM) as an Assistant Professor (Ramón y Cajal Fellow). In 2013 she received an ERC-Starting Grant awarded by the European Research Council to work on the project “Design and Applications of Unconventional Borylation Reactions”. In 2017, she was promoted to Associate Professor at UAM. Since November 2019, she serves as an Associate Editor of the ACS journal Organic Letters. Biologically active compounds (natural products and drugs) are a continuous inspiration for her research which includes asymmetric catalysis, boron chemistry and the development of metal-catalyzed transformations.

Dr. Alain de Mesmaeker
Syngenta, Switzerland
Design and synthesis of strigolactone derivatives using keteneiminiums as key intermediates: potential application to crop enhancement and crop protection.

Dr. Alain de Mesmaeker

Syngenta, Switzerland

Dr. Alain De Mesmaeker was born in Brussels. He has a BSc in Chemistry (1973-1978) from the Catholic University of Louvain, Belgium and a PhD in Chemistry (1978-1983) from the same university (Synthesis and thermal isomerisation of capto-dative substituted cyclopropanes, Prof. H. G. Viehe). This was followed by Post-doctoral Research (1983-1985) at the Weizmann Institute of Sciences, Rehovot, Israel (Total synthesis of carbacyclic analogues of Clavulanic Acid using radical reactions, Prof. M. D. Bachi). This was followed by various industrial appointments and promotions: 1985-1996: Group Leader in Central Research Laboratories, Ciba-Geigy, Basel, Switzerland (Natural Products synthesis, Intramolecular ketene cycloadditions, Radical Chemistry, Carbohydrate Chemistry, Nucleic Acids Research and Antisense strategy, Amide backbone modifications for Antisense Oligonucleotides, combinatorial Chemistry and Palladium catalyzed cross-coupling on solid-phase supports).
1997-2000: Head of Research Chemistry, Novartis Crop Protection Research (Insecticides, Herbicides and Fungicide Projects).
2000-2008: Global Head of Research Chemistry, Syngenta Crop Protection (Switzerland, United Kingdom, India).
2008-present: Principal Chemistry Expert and Principal Syngenta Fellow (Highest Scientific Level in Syngenta R&D), Syngenta Crop Protection and Crop Enhancement Research (Phytohormones), Stein, Switzerland.
He is a member of several scientific boards and organizing committees (e.g. Bürgenstock Conference on Stereochemistry, Swiss Chemical Society-Syngenta Symposium on Organic Chemistry, Swiss Industrial Chemistry Symposium, Jury member of the “Karrer Gold Medal Award” University of Zürich, Jury member of the” Ruzicka Prize” ETH Zürich, Chairman of the Werner Foundation, Belgian Organic Synthesis Symposium BOSS, Editorial Board of Helvetica Chimica Acta). In addition, he has received the following awards: Sandmeyer Award 2018 (the Swiss Chemical Society) and the Medal of the Slovak Chemical Society (2019).
He is currently the president of the Swiss Chemical Society.
He has >110 Publications, > 70 Patents and > 75 Invited lectures.

Dr. Rocco Paciello
BASF, Ludwigshafen, Germany
Homogeneous Catalysis@BASF

Dr. Rocco Paciello

BASF, Ludwigshafen, Germany

Dr. Rocco Paciello is the vice-president for homogeneous catalysis at BASF Ludwigshafen. Rocco Paciello completed his Ph.D degree in 1987 at the California Institute of Technology under the direction of Professor John Bercaw. He then spent two years as a Humboldt research fellow in Professor Wolfgang Herrmann's group at the Technical University in Munich. In 1989, he became a research chemist at DuPont CR&D in Wilmington, Delaware. In 1992, he moved to BASF in Ludwigshafen, Germany. After working as a research chemist and assistant plant manager, he became a research manager. He is presently an executive expert and responsible for homogeneous catalysis research.
His research interests are focused on finding new technical applications of transition metal catalyzed homogeneous catalysis (e.g., hydroformylations, carbonylations, hydrogenations, olefin synthesis, C-C-coupling). Areas of long-term interest have been asymmetric synthesis and use of CO2 as a C1-building block.

Welcome

Organization

Scientific Committee

Organizing Committee

Key Dates

Registration

Full in person participation registration

On-line participation registration

Full registration includes:

Cancellation and Refund

Payment Information

Scientific Program

Key areas

Conference Timeplan

Plenary Speakers

Dr. Kevin Campos

Prof. Armido Studer

Prof. Phil Baran

Dame Prof. Margaret Brimble

Prof. Brian Stoltz

Prof. Chaitan Khosla

Prof. John Sutherland

Prof. Klaus Mullen

Prof. Tim Noel

Dr. Oliver Thiel

Prof. Mariola Tortosa

Dr. Alain de Mesmaeker

Prof. Gonçalo Bernardes

Dr. Rocco Paciello

Plenary Talk Titles (under construction)

Abstract submission

Posters

Social Program

Conference Gala Dinner

Accommodation

Contacts Us

SPQ - Sociedade Portuguesa de Química Secretariat/Payments/Billing

General Information Organization/Program

SPONSORSHIP AND EXHIBITING

Platinum (Catalyst) Sponsor

Gold (Catalyst) Sponsor

Other Supporters

Media Partner

Full
in person participation registration

On-line
participation registration

SPQ - Sociedade Portuguesa de Química
Secretariat/Payments/Billing

General Information
Organization/Program